Findings

What do systematic reviews say?

22 questions · 22 findings · 6 reviews · Common Mental Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 14 · 63.6%GRADE not reported 0 · 0%Very low 4 · 18.2%Low 1 · 4.5%Moderate 2 · 9.1%High 1 · 4.5%

Selective serotonin reuptake inhibitors vs placebo

Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 148 participants
Very low

Tricylic antidepressant vs placebo

Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Hydrocortisone vs placebo

Quality of life at 3 months · adults experiencing acute traumatic stress symptoms

1 finding from 1 review

Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Very low

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life (EQ‐5D‐5L) ‐ 12 weeks · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 447 participants
High

Tricyclic antidepressants vs another medication

Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressants vs a combination of medications

Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Escitalopram vs placebo

Quality of life at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propranolol vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Psychological therapy vs enhanced or structured care

Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · people with somatoform disorders and medically unexplained physical symptoms

1 finding from 1 review

Non‐pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 497 participants
Moderate

Psychological therapy vs Waitlist/Usual Care

Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · people with somatoform disorders and medically unexplained physical symptoms

1 finding from 1 review

Non‐pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 730 participants
Low

Augmentation of current antidepressant (various) with quetiapine (150 mg/d to 300 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life (% max score of Q‐LES‐Q‐SF) ‐ Any dose Scale from: 0 to 100 (better) · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 884 participants
Moderate

Natural products vs placebo

Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found